Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 9

1.

A mathematical framework to determine the temporal sequence of somatic genetic events in cancer.

Attolini CS, Cheng YK, Beroukhim R, Getz G, Abdel-Wahab O, Levine RL, Mellinghoff IK, Michor F.

Proc Natl Acad Sci U S A. 2010 Oct 12;107(41):17604-9. doi: 10.1073/pnas.1009117107.

2.

Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies.

Russo A, Bazan V, Agnese V, Rodolico V, Gebbia N.

Ann Oncol. 2005 May;16 Suppl 4:iv44-49. Review.

PMID:
15923428
3.

Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications.

Kurman RJ, Shih IeM.

Int J Gynecol Pathol. 2008 Apr;27(2):151-60. doi: 10.1097/PGP.0b013e318161e4f5. Review.

4.

Molecular biology of colorectal cancer.

Gryfe R, Swallow C, Bapat B, Redston M, Gallinger S, Couture J.

Curr Probl Cancer. 1997 Sep-Oct;21(5):233-300. Review.

PMID:
9438104
5.

Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis.

Kurman RJ, Visvanathan K, Roden R, Wu TC, Shih IeM.

Am J Obstet Gynecol. 2008 Apr;198(4):351-6. doi: 10.1016/j.ajog.2008.01.005. Review.

6.

Biomolecular pathogenesis of borderline ovarian tumors: focusing target discovery through proteogenomics.

Vergara D, Tinelli A, Martignago R, Malvasi A, Chiuri VE, Leo G.

Curr Cancer Drug Targets. 2010 Feb;10(1):107-16. Review.

PMID:
20088785
7.

Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer.

Dahabreh IJ, Terasawa T, Castaldi PJ, Trikalinos TA.

Ann Intern Med. 2011 Jan 4;154(1):37-49. doi: 10.7326/0003-4819-154-1-201101040-00006. Review.

PMID:
21200037
8.

Role of proto-oncogene activation in carcinogenesis.

Anderson MW, Reynolds SH, You M, Maronpot RM.

Environ Health Perspect. 1992 Nov;98:13-24. Review.

9.

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.

Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, Schilsky RL.

J Clin Oncol. 2009 Apr 20;27(12):2091-6. doi: 10.1200/JCO.2009.21.9170. Review.

PMID:
19188670
Items per page

Supplemental Content

Support Center